<h3>享受 TipRanks Premium 50% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
<p>Sisram Medical Ltd.（（HK:1696））刚刚发布了一项更新。</p>
<p>Sisram Medical 已与其控股股东上海复星医药的间接全资子公司 Sinmait Medical Technology (Beijing) Co., Ltd.签署了一份非约束性谅解备忘录，探索在中国建立其基于能源的医疗设备的本地生产。拟议的合作将缩短供应链，增强本地响应能力，并将中国定位为亚太市场的区域生产和物流中心，但任何由此产生的安排可能构成香港上市规则下的可报告和关联交易，并仍需遵循最终协议和进一步的监管公告。</p>
<p>（HK:1696）股票的最新分析师评级为持有，目标价格为 HK$4.50。要查看 Sisram Medical Ltd.股票的完整分析师预测列表，请访问 HK:1696 股票预测页面。</p>
<p><strong>关于 Sisram Medical Ltd.的更多信息</strong></p>
<p>Sisram Medical Ltd.成立于以色列并在香港上市，专注于医疗技术领域，尤其是基于能源的医疗设备。该集团的核心战略市场包括中华人民共和国及更广泛的亚太地区，旨在扩大其制造和物流能力，以更好地满足日益增长的区域需求。</p>
<p><strong>平均交易量：</strong> 566,570</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> HK$2.03B</p>
<p>要全面评估 1696 股票，请访问 TipRanks 的股票分析页面。</p>

复星医药

富国恒生港股通创新药及医疗保健ETF

博时恒生港股通创新药精选ETF

招商中证生物科技主题ETF

香港医药

华夏中证全指医疗器械ETF

医疗器械ETF

复锐医疗科技

华夏中证生物科技主题ETF

国泰中证生物医药ETF

<p>复锐医疗科技有限公司已与新迈特医疗科技签署了一份非约束性谅解备忘录，以探索在中国本地生产其基于能源的医疗设备。此次合作旨在缩短供应链并增强本地响应能力，将中国定位为区域生产中心。该安排可能需遵循香港上市规则及进一步的监管公告。目前，复锐医疗股票（HK:1696）的分析师评级为持有，目标价为 4.50 港元</p>

<h3>Claim 50% Off TipRanks Premium</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，最大化您的投资组合潜力</li>
</ul>
</div><p>Sisram Medical Ltd. ( (HK:1696) ) just unveiled an update.</p>
<div class="lb-trans"><p>Sisram Medical Ltd.（（HK:1696））刚刚发布了一项更新。</p>
</div><p>Sisram Medical has signed a non-binding memorandum of understanding with Sinmait Medical Technology (Beijing) Co., Ltd., an indirect wholly owned subsidiary of its controlling shareholder Shanghai Fosun Pharmaceutical, to explore establishing local manufacturing for its energy-based medical devices in China. The proposed cooperation would shorten supply chains, enhance local responsiveness, and position China as a regional production and logistics hub for the Asia-Pacific market, but any resulting arrangements could constitute notifiable and connected transactions under Hong Kong listing rules and remain subject to definitive agreements and further regulatory announcements.</p>
<div class="lb-trans"><p>Sisram Medical 已与其控股股东上海复星医药的间接全资子公司 Sinmait Medical Technology (Beijing) Co., Ltd.签署了一份非约束性谅解备忘录，探索在中国建立其基于能源的医疗设备的本地生产。拟议的合作将缩短供应链，增强本地响应能力，并将中国定位为亚太市场的区域生产和物流中心，但任何由此产生的安排可能构成香港上市规则下的可报告和关联交易，并仍需遵循最终协议和进一步的监管公告。</p>
</div><p>The most recent analyst rating on (HK:1696) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.</p>
<div class="lb-trans"><p>（HK:1696）股票的最新分析师评级为持有，目标价格为 HK$4.50。要查看 Sisram Medical Ltd.股票的完整分析师预测列表，请访问 HK:1696 股票预测页面。</p>
</div><p><strong>More about Sisram Medical Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于 Sisram Medical Ltd.的更多信息</strong></p>
</div><p>Sisram Medical Ltd., incorporated in Israel and listed in Hong Kong, operates in the medical technology sector with a focus on energy-based medical devices. The Group targets core strategic markets including the People’s Republic of China and the broader Asia-Pacific region, aiming to expand its manufacturing and logistics capabilities to better serve growing regional demand.</p>
<div class="lb-trans"><p>Sisram Medical Ltd.成立于以色列并在香港上市，专注于医疗技术领域，尤其是基于能源的医疗设备。该集团的核心战略市场包括中华人民共和国及更广泛的亚太地区，旨在扩大其制造和物流能力，以更好地满足日益增长的区域需求。</p>
</div><p><strong>Average Trading Volume:</strong> 566,570</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 566,570</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> HK$2.03B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> HK$2.03B</p>
</div><p>For a thorough assessment of 1696 stock, go to TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>要全面评估 1696 股票，请访问 TipRanks 的股票分析页面。</p>
</div>

Sisram Medical Explores Local Manufacturing Partnership in China with Fosun Unit

Tip Ranks

复锐医疗科技正在与复星子公司在中国探索建立本地制造合作伙伴关系